NFL Biosciences SAS (PA:ALNFL) — Market Cap & Net Worth
Market Cap & Net Worth: NFL Biosciences SAS (ALNFL)
NFL Biosciences SAS (PA:ALNFL) has a market capitalization of $12.15 Million (€10.39 Million) as of June 21, 2026. Listed on the PA stock exchange, this France-based company holds position #26552 globally and #453 in its home market, demonstrating a -7.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NFL Biosciences SAS's stock price €0.82 by its total outstanding shares 12672242 (12.67 Million). Review NFL Biosciences SAS total liabilities to assess the company's total debt and financial obligations.
NFL Biosciences SAS Market Cap History: 2021 to 2026
NFL Biosciences SAS's market capitalization history from 2021 to 2026. Data shows change from $35.56 Million to $12.15 Million (-26.28% CAGR).
NFL Biosciences SAS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NFL Biosciences SAS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
634476.30x
NFL Biosciences SAS's market cap is 634476.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $35.56 Million | $39.00 | -$978.24K | 911703.55x | N/A |
| 2023 | $21.33 Million | $200.01K | -$3.75 Million | 106.66x | N/A |
| 2024 | $29.19 Million | $46.00 | -$2.08 Million | 634476.30x | N/A |
Competitor Companies of ALNFL by Market Capitalization
Companies near NFL Biosciences SAS in the global market cap rankings as of June 21, 2026.
Key companies related to NFL Biosciences SAS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
NFL Biosciences SAS Historical Marketcap From 2021 to 2026
Between 2021 and today, NFL Biosciences SAS's market cap moved from $35.56 Million to $ 12.15 Million, with a yearly change of -26.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €12.15 Million | -30.39% |
| 2025 | €17.45 Million | -40.20% |
| 2024 | €29.19 Million | +36.81% |
| 2023 | €21.33 Million | -26.72% |
| 2022 | €29.11 Million | -18.12% |
| 2021 | €35.56 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 20th, 2026 the market cap of NFL Biosciences SAS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.15 Million USD |
| MoneyControl | $12.15 Million USD |
| MarketWatch | $12.15 Million USD |
| marketcap.company | $12.15 Million USD |
| Reuters | $12.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more